Evidence mapPaperPMID 38879006Full record

ArticleThe Journal of biological chemistry2024

Glucoselysine, a unique advanced glycation end-product of the polyol pathway and its association with vascular complications in type 2 diabetes.

Hiroko Yamaguchi, Takeshi Matsumura, Hikari Sugawa, Naoko Niimi, Kazunori Sango, Ryoji Nagai

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. AldehydeFrontiers in medicine · 2026
    Article
  2. Starch Biopolymer Functionalized withCurrent drug delivery · 2026
    Article
  3. Review
  4. Review
  5. Potential of Orally Administered Quercetin, Hesperidin, andInternational journal of molecular sciences · 2025
    Review
  6. Review
  7. Article
  8. Review
  9. Raisin as a Functional Food: Antioxidant and Antiglycation Activity Assessed by Model Systems.Plant foods for human nutrition (Dordrecht, Netherlands) · 2024
    Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hiroko YamaguchiLaboratory of Food and Regulation Biology, Graduate School of Bioscience, Tokai University, Kumamoto, Japan.
Takeshi MatsumuraDepartment of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Hikari SugawaLaboratory of Food and Regulation Biology, Department of Food and Life Science, School of Agriculture, Tokai University, Kumamoto, Japan.
Naoko NiimiDiabetic Neuropathy Project, Department of Diseases and Infection, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Kazunori SangoDiabetic Neuropathy Project, Department of Diseases and Infection, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Ryoji NagaiLaboratory of Food and Regulation Biology, Graduate School of Bioscience, Tokai University, Kumamoto, Japan; Laboratory of Food and Regulation Biology, Department of Food and Life Science, School of Agriculture, Tokai University, Kumamoto, Japan. Electronic address: nagai-883@umin.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glucoselysine (GL) is an unique advanced glycation end-product derived from fructose. The main source of fructose in vivo is the polyol pathway, and an increase in its activity leads to diabetic complications. Here, we aimed to demonstrate that GL can serve as an indicator of the polyol pathway activity. Additionally, we propose a novel approach for detecting GL in peripheral blood samples using liquid chromatography-tandem mass spectrometry and evaluate its clinical usefulness. We successfully circumvent interference from fructoselysine, which shares the same molecular weight as GL, by performing ultrafiltration and hydrolysis without reduction, successfully generating adequate peaks for quantification in serum. Furthermore, using immortalized aldose reductase KO mouse Schwann cells, we demonstrate that GL reflects the downstream activity of the polyol pathway and that GL produced intracellularly is released into the extracellular space. Clinical studies reveal that GL levels in patients with type 2 diabetes are significantly higher than those in healthy participants, while N

Indexed as

Diabetes Mellitus, Type 2Glycation End Products, AdvancedAgedAldehyde ReductaseAnimalsDiabetic AngiopathiesFemaleHumansImidazolesLysineMaleMiceMice, KnockoutMiddle AgedOrnithinePolymersAldehyde ReductaseGlycation End Products, AdvancedImidazolesLysineNdelta-(5-hydro-5-methyl-4-imidazolon-2-yl)ornithineOrnithinePolymerspolyoladvanced glycation end-products (AGEs)aldose reductasebiomarkerblooddiabetesfructoseglucoselysineglucose metabolismhyperglycemiamass spectrometry (MS)polyol pathway

Identifiers

PMID38879006
PMCPMC11283207

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.